A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy

For estrogen receptor (ER)-negative breast cancer patients, paclitaxel (P), doxorubicin (A) and cyclophosphamide (C) neoadjuvant chemotherapy (NAC) is the standard therapeutic regimen. Pathologic complete response (pCR) and residual disease (RD) are common surrogate measures of chemosensitivity. Aft...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Mol Biosci
Main Authors: Chen, Yanhua, Cai, Hao, Chen, Wannan, Guan, Qingzhou, He, Jun, Guo, Zheng, Li, Jing
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020
Assuntos:
Molecular Biosciences
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7109260/
https://ncbi.nlm.nih.gov/pubmed/32269999
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmolb.2020.00034
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados